TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Nuwellis ( (NUWE) ) has provided an update.
On August 19, 2025, Nuwellis, Inc. announced its intention to acquire Rendiatech, Ltd., an Israeli company specializing in urine flow and kidney monitoring technologies. This acquisition aims to enhance Nuwellis’ technology platform by incorporating continuous renal health monitoring, potentially offering clinicians better insights into fluid status and kidney function. The deal is expected to close in the fourth quarter of 2025, subject to due diligence, board approval, and closing conditions.
The most recent analyst rating on (NUWE) stock is a Hold with a $6.00 price target. To see the full list of analyst forecasts on Nuwellis stock, see the NUWE Stock Forecast page.
Spark’s Take on NUWE Stock
According to Spark, TipRanks’ AI Analyst, NUWE is a Neutral.
Nuwellis’ overall stock score is primarily impacted by its financial performance, characterized by significant losses and negative cash flows. Technical indicators suggest bearish momentum, and valuation metrics are unattractive due to negative earnings. While the company has taken positive strategic steps, immediate financial challenges and corporate events like delisting risks weigh heavily on the stock’s outlook.
To see Spark’s full report on NUWE stock, click here.
More about Nuwellis
Nuwellis, Inc. operates in the medical device industry, focusing on ultrafiltration technology and expanding into renal health monitoring.
Average Trading Volume: 1,049,376
Technical Sentiment Signal: Sell
Current Market Cap: $5M
For an in-depth examination of NUWE stock, go to TipRanks’ Overview page.